The physician's choice of antiepileptic drug for a particular patient should be based on firm evidence. The current body of evidence generated from randomized, controlled monotherapy trials is discussed. Attention is focused on four recently published randomized trials in which monotherapy with one drug is compared with monotherapy with another. The limitations of our current knowledge are discussed and some suggestions for future research are made.